Reason for request
Inclusion
-
Clinical Benefit
Substantial |
The actual benefit of INLYTA in the treatment of renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine is substantial. |
Clinical Added Value
minor |
The Committee assigns INLYTA a minor improvement in actual benefit (IAB level IV) in terms of efficacy by comparison with NEXAVAR (sorafenib) in the second-line treatment of advanced renal cell carcinoma. |
Comments without ASMR value |
The Committee cannot quantify the therapeutic benefit of INLYTA in current therapeutic use, i.e. as second-line treatment after the failure of sunitinib. |
English version
Contact Us
Évaluation des médicaments